GLP-1 Drug Food Savings: Users Cut £418 Yearly

GLP-1 Drug Food Savings are proving substantial for households. Users are collectively cutting their grocery bills by an average of £418 annually, and this reduction comes as the adoption of these medications has nearly tripled over the past two years, now reaching 1.9 million adults. But this surge signals a major shift in consumer spending habits. It's having a noticeable impact on the retail food sector.

The numbers are stark. Research shows that households with at least one GLP-1 user spent £780 million less on groceries than expected, compared with similar families not taking these drugs. That's a huge shift. And it's backed by 299 million fewer items purchased during a recent analysis in February alone. So this pattern of reduced consumption translates directly into the annual £418 saving for households integrating these weight-loss medications.

Rapid Expansion of GLP-1 Use

The prevalence of GLP-1 drugs, including well-known options like Mounjaro and Wegovy, has seen a dramatic rise across Great Britain. Currently, more than 6.3% of households now include at least one individual taking these medications. This marks a sharp climb from previous years, with usage standing at 4.1% of households in 2025 and just 2.3% in 2024. The data clearly demonstrates how quickly these treatments are moving into the mainstream.

But the real driver is simple. More people are using GLP-1s specifically for weight loss now. Historically prescribed primarily for type 2 diabetes, these drugs are now being used by 68% of individuals explicitly to manage their weight, so they're opening themselves up to a far broader audience.

Altered Eating Habits and Consumer Choices

GLP-1s don't just cut calories. They're fundamentally reshaping how users engage with food, guiding consumption by genuine hunger rather than deeply ingrained habits, established routines, or restrictive diets. And here's the key. Over half of users, 52%, now describe their eating approach as "mindful.

Here's the new insight: 54% of people on these jabs felt fewer cravings and a clear drop in what's called "food noise," those constant thoughts about eating. But 11% of users stopped enjoying their usual favorite foods or drinks. That signals a profound shift in taste preferences.

Treats and Dining Out Face Changes

Users are actively cutting back on indulgent items. But they're not just saying it. A substantial three-quarters, 75%, reported eating less chocolate, and a similar proportion, 72%, reduced their consumption of crisps, and these self-reported changes are corroborated by actual shopping data showing chocolate confectionery spending fell 18 percentage points more in GLP-1 user households compared to non-user households.

The influence of GLP-1s extends beyond the kitchen. But when dining out, 40% of people on these drugs wanted smaller restaurant portions. And 26% of users requested dedicated GLP-1-friendly sections on menus, highlighting a need for public eateries to cater to these new dietary patterns that are reshaping how we order and eat. It's a big shift.

Unexpected Side Effects Drive New Purchases

The primary focus remains on GLP-1 Drug Food Savings. But these medications can also trigger unanticipated side effects that influence other areas of spending, including a condition known as "Ozempic mouth" characterized by dry mouth and bad breath. It's prompted some users to buy more specific hygiene products.

This has led to a significant uptick in sales:

• Mouthwash sales increased by 20 percentage points in GLP-1 user households.
• Chewing gum sales rose by 24 percentage points in GLP-1 user households.

Chantel Kennaugh, head of public sector and nutrition GB for Worldpanel by Numerator, observed that these drugs are "fundamentally disrupting how people engage with food and drink, with ripple effects already being felt across grocery and lifestyle, forcing brands and businesses to adapt at pace.

Retailers are already responding. Marks & Spencer, for example, introduced a line of "nutrient-dense" foods at the start of the year, targeting customers who are naturally eating less and want more from their meals. But Ocado went further. The online grocer created a virtual "weight management" aisle, curating suitable products for this demographic so shoppers don't have to hunt for them.

Health benefits and GLP-1 Drug Food Savings are clear, but cost is a major hurdle. Worldpanel's research found that price has re-emerged as the primary barrier to continued medication use, with a notable two-fifths of users stopping their treatment in 2026 simply because they couldn't afford it. That's 41%.